Susunod

Auto-play

MARS: mutation-adjusted risk score for advanced systemic mastocytosis

2 Mga view • 07/09/23
Ibahagi
I-embed
administrator
administrator
Mga subscriber
0

Andreas Reiter, MD, University Medical Centre, Mannheim, Germany, discusses how a mutation-adjusted risk score (MARS) may improve treatment stratification for advanced systemic mastocytosis (AdvSM). This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.

Magpakita ng higit pa
0 Mga komento sort Pagbukud-bukurin Ayon
Mga Komento sa Facebook

Susunod

Auto-play